Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.360
-0.030 (-2.16%)
At close: Dec 5, 2025, 4:00 PM EST
1.350
-0.010 (-0.74%)
After-hours: Dec 5, 2025, 6:11 PM EST
Rein Therapeutics Employees
Rein Therapeutics had 11 employees as of December 31, 2024. The number of employees decreased by 4 or -26.67% compared to the previous year.
Employees
11
Change (1Y)
-4
Growth (1Y)
-26.67%
Revenue / Employee
n/a
Profits / Employee
-$5,353,182
Market Cap
35.75M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RNTX News
- 4 weeks ago - Why Is Rein Therapeutics Stock Trading Higher On Monday? - Benzinga
- 2 months ago - Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 2 months ago - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 3 months ago - Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 4 months ago - Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 - GlobeNewsWire
- 5 months ago - Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders - PRNewsWire
- 6 months ago - US FDA puts on hold Rein Therapeutics' lung disease drug trial - Reuters
- 6 months ago - Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire